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Abstract: In vitro studies show that diclofenac inhibits enzymatic steroid glucuronidation. This study
was designed to investigate the influence of diclofenac on the excretion of stanozolol and
3′-hydroxystanozolol via analyses in hair, blood and urine in vivo in a rat study. Brown Norway rats
were administered with stanozolol (weeks 1–3) and diclofenac (weeks 1–6). Weekly assessment of
steroid levels in hair was complemented with spot urine and serum tests. Levels of both stanozolol
and 3′-hydroxystanozolol steadily increased in hair during stanozolol treatment and decreased
post-treatment, but remained readily detectable for 6 weeks. In contrast, compared to control rats,
diclofenac significantly reduced urinary excretion of 3′-hydroxystanozolol which was undetectable in
most samples. This is the first report of diclofenac altering steroid metabolism in vivo, detrimentally
affecting detection in urine, but not in hair, which holds considerable advantages over urinalysis for
anti-doping tests.
Keywords: steroid; metabolism; anti-inflammatory drug; inhibition
1. Introduction
The major elimination and deactivation pathway for anabolic steroids (AS) and their
phase I metabolites is through glucuronide conjugation (phase II metabolism) followed by
excretion in urine [1–4]. The glucuronidation of AS is mainly catalysed by the enzyme UDP
glucuronosyltransferase 2 family, polypeptide B17 (UGT2B17). Inter-individual and inter-ethnic
variations in the prevalence of deletion polymorphism in the gene coding of the UGT2B17 enzyme
were noted to influence the urinary excretion of AS [5,6]. Furthermore, UGTs are not only involved in
the metabolism of AS, but they also contribute to the metabolism of various compounds including
non-steroidal anti-inflammatory drugs (NSAIDs) [1]. The NSAIDs ibuprofen and diclofenac are
commonly used by athletes for the treatment of pain and inflammation [7–12], and it has been reported
that both drugs competitively inhibit the testosterone glucuronidation activity of UGT2B17 and other
UGTs, in vitro [13]. Common dietary substances such as white tea and green tea [14] and red wine [15],
have also exhibited similar inhibitory effects in in vitro studies. A recent study investigated the
effects of two NSAIDs (ibuprofen and diclofenac) on excretion of a single dose of testosterone in 23
male volunteers with two (39%), one (33%) or no (28%) allele of the UGT2B17 gene. Intramuscular
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administration of the equivalent of 360 mg of testosterone along with the maximum safe dosage
of NSAID had no effects on the urinary ratio of testosterone glucuronide (TG) to epitestosterone
glucuronide (EG). However, this result was attributed to a slight increase in EG secretion coupled with
a slight decrease in TG section. The authors also postulated that oral steroid administration may result
in more marked effects owing to higher levels of metabolism via the liver [16].
Considering that such genetic and metabolic variations may limit the efficacy of urinalysis
in doping tests, urinalysis, if used as a stand-alone test, is susceptible to confounding doping
results [1–4,17,18]. Since impaired glucuronidation leads to reduction in the urinary excretion of
AS, it can be assumed that the levels of unconjugated AS and their phase I metabolites in the systemic
circulation will be elevated and thus available to be incorporated into hair and other body tissues [6].
Thus, hair analysis and blood analysis can provide complementary information to urinalysis to prevent
false negative doping results. To investigate this option further, in vivo studies are required to establish
a relationship between AS levels detected in hair, urine and blood.
Aims and Research Hypotheses
With the view of addressing concerns over masking effects of NSAIDS in doping testing, this
study aims to investigate the potential application of hair analysis when urinary tests are impaired.
Specifically, this study was designed to investigate the influence of diclofenac on the excretion of
stanozolol and 3′-hydroxystanozolol via analyses in hair, blood and urine in vivo in a rat study.
Diclofenac was selected as the inhibition profiles were fully characterised in in vitro studies against
UGT2B17 and UGT2B15 with diclofenac being the most potent of the NSAID inhibitors [13]. Based on
in vivo studies, we expected that concomitant administration of diclofenac with stanozolol will:
H1: increase the circulating concentration of stanozolol and 3′-hydroxystanozolol (blood);
H2: decrease the concentration of 3′-hydroxystanozolol in urine;
H3: increase the concentration of stanozolol and 3′-hydroxystanozolol in hair; and
H4: whilst the concentrations of stanozolol and 3′-hydroxystanozolol in hair are expected to
gradually decrease after ceasing stanolozol treatment, both stanozolol and 3′-hydroxystanozolol
in hair will remain detectable for the same period after the treatment cycle.
The study design involved administration of stanozolol to a control group and two treatment
groups which received diclofenac (Figure 1) with sampling of hair, blood and urine as indicated for
analysis of parent steroid and its hydroxylated metabolite.
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2. Results
2.1. Effect of Diclofenac on the Serum Concentration of Stanozolol and 3′-Hydroxystanozolol
The concentrations of stanozolol and 3′-hydroxystanozolol in rat serum during the seven weeks
of the study are shown in Figure 2A,B. As expected, mean levels of stanozolol increased during the
three treatment weeks for all three groups (to ca. 30 ng/mL) with a steady decrease in levels in the
subsequent four weeks post-treatment (Figure 2A). Statistical analysis reveals significant differences
with diclofenac treatment for S1 and a large partial η2 (ABC) effect size for S1 (Table S1). Large Cohen’s
d effect sizes are also revealed for S1 (A-B; A-C), S4 (A-C) and S6 (A-C; B-C) (Table S1). Test sensitivity
data are in the range of 93–100% for S2–S5 (Table S2) suggesting that stanozolol and its key metabolite
were detected in most samples with only one false negative result.
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Figure 2. Concentrations of stanozolol and 3′-hydroxystanozolol in serum ((A,B) respectively) and
stanozolol in urine samples ((C) pre-treatment (urine 1) and (D) one hour post-treatment (urine 2)) from
group A (5 mg/kg stanozolol only), group B (5 mg/kg stanozolol + 1 mg/kg diclofenac) and group C
(5 mg/kg stanozolol + 5 mg/kg diclofenac). Error bars represent standard deviations. Different letters
(A,B) denote st tistically significant iffere ces between the treatment groups (p < 0.05) at a sampling
point. Effect sizes are given in Table S1. Test sensitivity ov r time differences, are displayed in Table S2.
As expected, relative to the parent drug, lower sera levels of 3′-hydroxystanozolol were found
with an increase over weeks S2–S4 (to ca. 15 ng/mL) with a steady decrease in levels in subsequent
weeks post-treatment. Significant differences upon treatment with diclofenac appeared at week S4
and a large partial η2 (ABC) effect size occurred at S4 and S5 (Table S1). Large Cohen’s d effect sizes
are found at S4 and S5 (Table S1) with test sensitivity between 78–100% for S2–S5 (Table S2). Effect
sizes are used to identify apparent differences in the figure which fail to reach statistical significance
but are likely to be present and practically meaningful. Failing to reach statistical significance in such
cases are the combined function of the small sample size and relatively large SD. The metabolite,
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3′-hydroxystanozolol, was not detectable in any of the first blood samples that were collected one hour
after the administration of drugs.
2.2. Effect of Diclofenac on the Urinary Excretion of Stanozolol and 3′-Hydroxystanozolol
The average concentrations of stanozolol in rat urine 1 (30 min post anaesthesia) and urine 2
(60 min post drug injection) in each group during stanozolol treatment and post-stanozolol treatment
are presented in Figure 2C,D. Urinalysis revealed increasing levels of stanozolol in urine 2 samples
as treatment progressed with a decrease after cessation of stanozolol administration. Administration
of diclofenac resulted in a large partial η2 (ABC) effect size observed for S3 (ABC) and large Cohen’s
effect sizes occur for S2, S3 and S6 (Table S1). Sensitivity test data for stanozolol were high (94–100%)
over S2–S5 (Table S2) showing only 1 false negative result.
3′-Hydroxystanozolol data in urine samples are not depicted because the metabolite was only
detected in urine 1 samples in Group A in S2 (mean concentration for n = 6 was 8.241 ± 7.212 ng/mL);
and at a low level in S3 in 4 animals of the 6 (mean concentrations = 0.188 ± 0.147 ng/mL (n = 4)).
In S3, 3′-hydroxystanozolol was detected in urine 1 samples from one animal in each Group B
(0.056 ng/mL) and Group C (0.076 ng/mL). 3′-hydroxystanozolol was not detected in any of the urine
2 samples. For 3′-hydroxystanozolol in urine 1, diclofenac administration resulted in large effect sizes
being observed at S2 and S3 (Cohen’s d and partial η2), with significant differences at S2 (Table S1).
Sensitivity test data for 3′-hydroxystanozolol in urine 1 and 2 samples were very low between 0–36%
for S2–S5, reflecting a high number of false negatives (Table S2).
2.3. Effect of Diclofenac on the Incorporation of Stanozolol and 3′-Hydroxystanozolol in Hair
The concentrations of 3′-hydroxystanozolol and stanozolol in rat hair during the seven weeks of
the study are presented in Figure 3. During the stanozolol treatment period, elevations in hair levels of
stanozolol and 3′-hydroxystanozolol were observed. In all three groups, the maximum concentration
of stanozolol in hair was reached on the 6th week of the study, i.e., three weeks after stopping the
stanozolol treatment. However, the peak concentration of 3′-hydroxystanozolol in hair in all three
groups was reached on the 3rd week of the study, i.e., after two weeks of stanozolol treatment, and
then decreased gradually.
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for the metabolite. There were significant differences owing to diclofenac at S3 for the parent drug 
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Figure 3. Concentrations of stanozolol (A) and 3′-hydroxystanozolol (B) in hair samples from group A
(5 mg/kg stanozolol only), group B (5 mg/kg stanozolol + 1 mg/kg diclofenac) and group C (5 mg/kg
stanozolol + 5 mg/kg diclofenac). Error bars represent standard deviations. Different letters denote
statistically significant differences between the treatment groups (p < 0.05). Effect sizes are given in
Table S1.
After cessation of stanozolol treatment, the levels decline at S6 for parent drug and S4 onwards
for the metabolite. There were significant differences owing to diclofenac at S3 for the parent drug
reflecting a decrease in hair uptake. For the stanozolol levels, diclofenac treatment resulted in the
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partial η2 effect sizes being large at S2 and S3 with significant difference at S3 and with large values for
Cohen’s d effect size at S2–S5 (Table S1). The test sensitivity is between 93–100% across S2–S6 (Table S2).
During the latter weeks, levels of stanozolol in hair were elevated up to S5, and then decreased, but
still present in abundance, in all three groups. For 3′-hydroxystanozolol, large partial η2 effect sizes
are seen for S2–S4 and Cohen’s effect sizes for S2–S5 reflecting higher levels of metabolite in hair,
especially for the group receiving 1 mg/kg diclofenac with the stanozolol treatment.
2.4. Relationship between Levels of Stanozolol and 3′-Hydroxystanozolol in Hair, Urine and Blood
Table 1 displays the relationships between hair levels of stanozolol and 3′-hydroxystanozolol
and levels in urine and blood two weeks prior to the hair sample collection, separately for each
experimental group. During the stanozolol treatment period (S1–S3), a relationship (r > 0.3) with urine
levels of stanozolol and 3′-hydroxystanozolol was only observed in the two groups that also received
diclofenac. In Group A, hair levels after the treatment period showed a positive relationship with
levels in blood. In groups B and C, no clear pattern is observed, however, it was notable that several
positive relationships between levels in S3 (last treatment week) in body fluids and two weeks later
in hair (S5) turned negative one week later. The inverse pattern is also observable in Figures 2 and 3,
where in hair, stanozolol concentration—at the group level—peaked at S5 (2 weeks after the stanozolol
treatment ceased), whereas the metabolite level peaked at S3 (end of stanozolol treatment). The pattern
was reversed for blood, albeit less pronounced, where stanozolol concentration peaked at S3 whereas
the 3′-hydroxystanozolol level was the highest in all 3 groups at S4.
Table 1. Relationship between levels of stanozolol and 3′-hydroxystanozolol in hair and in urine and
blood samples for the closest corresponding time period (2 weeks).
Stanozolol Treatment Post Stanozolol Treatment
Weeks 1 & 2 Week 3 Week 4 Week 5 Week 6
Hair Stanozolol
Urine 1ST - S2 (−) ** S3 (−) ***
Urine 2ST - S3 (−) *
Serum ST - S1 (+) ** S2 (+) * S3 (+) * S4 (+) *
Group A Hair 3′-Hydroxystanozolol
Urine 1HST - S2 (−) * S3 (−) ***
Urine 2HST -
Serum HST - S2 (−) * S3 (+) * S4 (+) *
Hair Stanozolol
Urine 1ST - S2 (+) *** S4 (−) *
Urine 2ST - S2 (−) ** S3 (−) *
Serum ST - S1 (−) *** S3 (−) * S4 (−) **
Group B Hair 3′-Hydroxystanozolol
Urine 1HST - S3 (+) ***
Urine 2HST -
Serum HST - S2 (+) *** S3 (-) * S4 (+) ***
Hair Stanozolol
Urine 1ST - S2 (−) * S3 (+) *** S4 (−) **
Urine 2ST - S2 (−) * S3 (+) *
Serum ST - S1 (−) * S2 (+) *** S3 (+) *** S4 (−) **
Group C Hair 3′-Hydroxystanozolol
Urine 1HST - S3 (+) ***
Urine 2HST -
Serum HST - S2 (−) * S3 (+) ** S4 (−) *
S = sampling points; ST = stanozolol; HST = 3′-hydroxystanozolol; * = 0.3 < r > 0.5; ** = 0.5 < r > 0.7; *** = r > 0.7.
Not shown (cell is empty) if r < 0.3; (−) denotes negative correlation; (+) denotes positive correlation.
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3. Discussion
3.1. Effect of Diclofenac on Stanozolol Distribution
3.1.1. H1: Increase the Circulating Concentration of Stanozolol and 3′-Hydroxystanozolol (Blood)
The experimental design featured the capability of assessing the effects of diclofenac on stanozolol
profiles during co-administration and for a four week period after cessation of stanozolol to capture the
effect on extended metabolism. Diclofenac administration increased the circulating levels of stanozolol
and 3′-hydroxystanozolol (H1) as assessed by significant differences and/or large effects sizes for
the period S1, S4 and S6 for stanozolol and S3–S6 for 3′-hydroxystanozolol. The effect is notable
on the levels of metabolite over the final weeks (S4–S6). This disruptive effect on metabolism is in
line with inhibition of glucuronidation by diclofenac, whereby a build-up of 3′-hydroxystanozolol
occurs. The early phase significant difference for stanozolol levels may result from a failure to clear the
metabolite owing to impaired glucuronidation. However, the low levels of metabolite at S1 (below the
LLOQ) point to another explanation such as impaired phase 1 metabolism affecting generation of the
hydroxylated metabolite.
3.1.2. H2: Decrease the Concentration of 3′-Hydroxystanozolol in Urine
Urinalysis results followed an expected pattern in that levels of 3′-hydroxystanozolol were below
the limit of quantification in all but 2 of the diclofenac treated rat samples (out of a total of 144 samples
taken) despite the assay design to measure combined free metabolite and de-glucuronidated metabolite
in line with testing protocols for stanozolol [19,20]. In contrast, 3′-hydroxystanozolol was readily
detectable in most of the samples taken at S2 (mean concentration 8.241–7.212 ng/mL) and S3
from rats without diclofenac treatment. Low quantities of stanozolol were measured in both
urine 1 and 2 samples, which highlighted the absence of quantifiable levels of the metabolite or
its glucuronide conjugate. In summary, administration of diclofenac decreased the urinary levels of
3′-hydroxystanozolol to below the limit of quantification in all except 1 rat at S3 for both doses of
diclofenac. This outcome is supported by large effect sizes at S2 and S3, with significant differences at
S2 (Table 1).
3.1.3. H3: Increase the Concentration of Stanozolol and 3′-Hydroxystanozolol in Hair
After one week of stanozolol treatment, very high levels of the parent drug and its metabolite
(relative to the LLOQ; 0.5 pg/mg) were measured in hair samples in all sampling weeks S2–S6. These
levels of up to 600× and 120× the LLOQ for stanozolol and 3′-hydroxystanozolol respectively are
present in every sample taken after week one of treatment. Treatment with diclofenac resulted in an
initial decrease in hair stanozolol levels at week S3. An analogous variable picture is observed for
3′-hydrozystanozolol where diclofenac treatment resulted in higher levels at S3–S5 for at least one
diclofenac dose regime. Thus, diclofenac has variable effects on hair uptake of stanozolol, but increased
levels are seen after two weeks of administration. This increase is off-set for 3′-hydroxystanozolol
until week S4; that is three weeks after initiation of treatment. Thus, variable effects are observed for
diclofenac on stanozolol and 3′-hydroxystanozolol levels in hair. In each case, the levels present for
parent drug and metabolite greatly exceed the LLOQ. This variability may arise from the effects of
large doses of diclofenac coupled to the complex uptake modes into hair which depend on numerous
factors ranging from levels and activity of UGT enzymes, to the basicity of the analyte itself.
3.1.4. H4: Whilst the Concentrations of Stanozolol and 3′-Hydroxystanozolol in Hair are Expected to
Gradually Decrease after Ceasing Stanolozol Treatment, Both Stanozolol and 3-Hydroxystanozolol in
Hair Will Remain Detectable for up to Three Weeks
The levels of stanozolol in hair had started to decline at week seven, a full three weeks after
administration stopped. The maximum levels were observed in week S5 at some 600 times the
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LLOQ. For week seven, the levels had dropped considerably but were still some ten times the LLOQ.
Unfortunately, the available data are not sufficient to estimate how long the parent drug stanozolol still
remains detectable in hair, but extrapolating the rate of decline, future studies should continue with
weekly sampling up to 6 weeks (twice the treatment period) after the treatment ceased. In contrast,
the levels of 3′-hydroxystanozolol reached a peak at week S3 and declined thereafter. Although they
had diminished, the levels of the metabolite in hair were still considerably above the LLOQ at week
S6. The overall results from the hair analysis suggest that diclofenac did not inhibit the incorporation
of stanozolol or 3′-hydroxystanozolol into hair. Following cessation of stanozolol treatment, both
compounds were detected in hair in all three groups up to four weeks after the administration of the
last dose of stanozolol whilst diclofenac administration continued.
3.2. Implications of the Results and Future Perspectives
The results are of particular interest to those involved in anti-doping tests. One key finding is that
hair analysis is far superior to urinalysis for the out of competition detection of synthetic steroids as part
of an anti-doping test regime. In spite of three weeks of continuous daily dosing (for 6 days per week),
levels of the steroid metabolite 3′-hydroxystanozolol in urine were below the limit of quantification
for this assay, whereas for the same dosage, the levels in hair were over one hundred-fold above
the level of quantification. A further concern for doping control is that the NSAID led to reduced
levels of metabolite in urine leading to potential false negative test results. On the contrary, hair
was unaffected. The difficulties of utilising urinalyses for stanozolol based on quantification of the
hydroxylated metabolite are seen with the sensitivity results showing a very high proportion of false
negatives (Table S2). In contrast, for the parent steroid, levels in hair are over 200-fold above the
LLOQ with detection being feasible for up to three weeks after cessation of the steroid administration.
Although the study was conducted in rats, the method used provided a limit of detection below test
criteria for stanozolol and 3′-hydroxystanozolol used by the World Anti-Doping Agency (WADA)
stablished measure of Minimum Required Performance Levels (2 ng/mL) (WADA TD2014MRPL).
In line with the standard doping testing protocol, the test method used for hair incorporated
both 3′-hydroxystanozolol and the de-glucuronidated conjugate [20]. In addition to the capability of
a single test covering several months (as 1 cm of cranial hair growth equates to ca. 1 month), hair
analysis provides a number of advantages over urine or serum testing. The known advantages prior
to the study and presented in this paper are catalogued as reduced infection risk, non-invasive sample
collection, facile sample storage and transport, reduced risk of tampering and ease of chain of custody.
Further advantages are that the test does not rely on knowing the location of an athlete or having
them available for testing on a regular basis. In support of hair-based testing, this study provides
strong evidence that detecting a synthetic steroid in hair is unaffected by temporary compromised
metabolism via concomitant administration of NSAID. Although further research is warranted,
including human studies, the results demonstrate, for the first time in vivo, that diclofenac, an NSAID
interacts with steroid metabolism, a long suggested pathway based on in vitro studies. The results
indicate that diclofenac significantly inhibits the urinary excretion of 3′-hydroxystanozolol in rats.
However, diclofenac was found to have no inhibitory effect on the incorporation of stanozolol and
3′-hydroxystanozolol in hair. Even after ending stanozolol treatment, stanozolol was detectable in the
hair of most animals after three weeks. In contrast, stanozolol was detectable in the urine of only two
animals (out of 17) three weeks after cessation of stanozolol treatment, whereas 3′-hydroxystanozolol
was not detectable in the urine samples of any animals. These results highlight the difficulties of the
detecting both compounds in urine in comparison to hair analyses. Blood analysis can also provide
important information on drug use, but it is a short term measure and an invasive method compared
to hair.
It is envisaged that results from this study can be extended to other drugs in the synthetic steroids
family and move towards developing hair-based testing for a wider range of synthetic steroids as a part
of new doping control measures in competitive sport. In the past, researchers have found it difficult to
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detect 3′-hydroxystanozolol in hair. Cirimele et al. reported the detection of stanozolol in scalp hair of
a bodybuilder who declared regular use of stanozolol [21]. However, 3′-hydroxystanozolol was not
detectable in hair under the analytical conditions employed by the authors. Similarly, in another study
carried out by Shen et al. stanozolol was detectable in guinea pig hair after administering stanozolol at
a single high dose of 60 mg/kg, whereas, 3′-hydroxystanozolol was not detectable [22]. However, the
method developed for the current study is capable of detecting stanozolol and 3′-hydroxystanozolol
in rat hair after administering stanozolol for 6 days at a dose of 5.0 mg/kg/day that is considered
equivalent to those levels abused by athletes [6].
4. Materials and Methods
4.1. Chemicals and Reagents
Reference standards for stanozolol, 3′-hydroxystanozolol, 3′-hydroxystanozolol glucuronide,
stanozolol D3, 3′-hydroxystanozolol D3 were purchased from LGC standards (Teddington, UK).
All other chemicals were purchased from Sigma Aldrich (Poole, UK). β-Glucuronidase from E. coli
was purchased from Roche Diagnostics (Burgess Hill, UK). For the animal experiments, stanozolol,
ketamine (2.5%), xylazine (Rompun, 2%) and diclofenac were purchased from Desma (Madrid, Spain),
Ko˝bányai Gyógyszerárugyár (Budapest, Hungary), Haver-Lockhart Laboratories (Shawnee, KS, USA)
and Sigma Aldrich (Deisenhofen, Germany) respectively.
4.2. Animals
Eighteen male, Brown Norway rats were purchased from Charles River laboratories (Sulzfeld,
Germany). Each animal weighed around 280–340 g and was approximately 5 months old. Rats were
housed in groups of three individuals in standard laboratory cages and kept in a constant room
temperature environment with an alternating 12-h light-dark cycle. Food and water were available
ad-libitum. The administration of drugs and sample collection were conducted under the institutional
license of the Department of Anatomy, Histology and Embryology, Semmelweis University (Budapest,
Hungary) in accordance with the EC Council directives on laboratory animals (86/609/EEC) [23].
4.3. Administration of Diclofenac and Stanozolol
Rats were divided into three groups of six animals each (Groups A, B and C). Diclofenac, dissolved
in saline, was administered daily, subcutaneously, to each animal belonging to group B and C, six days
a week at doses detailed in Figure 1. Two days after the beginning of diclofenac treatment, animals of
all three groups received stanozolol (in saline) intraperitoneally [22], at a dose of 5 mg/bmkg/day,
six days a week. The diclofenac treatment lasted for a period of six weeks, whereas the stanozolol
treatment lasted for three weeks (Figure 1). Stanozolol and diclofenac were injected at the same time
on every treatment day from Monday to Saturday (inclusive).
Group B received diclofenac at a daily dosage of 1 mg/bmkg and the recommended daily dose of
diclofenac in adults is 75 to 150 mg daily. Thus, depending on the body weight of adult individuals,
dosage of diclofenac received by Group B approximately resembled the typical daily dose of diclofenac
in adults. The dose of stanozolol selected was in line with previous steroid studies using rat models
and considered equivalent to those abused by humans on a milligram per kilogram of body weight
basis [24–27]. Group C received a dose of 5 mg/bmkg to ascertain the effects of high dosage on steroid
distribution. Negative controls were obtained by collecting hair, blood and urine samples prior to the
administration of the drugs to the rats.
4.4. Sample Collection
The hair segments, blood and two urine samples were collected under anaesthesia (ketamine and
xylasine mixture) once every week for five weeks and at week seven (Figure 1). Sample collections
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were scheduled for Wednesdays (after two days of the weekly treatment cycle) in all samples but S2,
where sample collection took place on Tuesday (on the second day of the weekly treatment cycle).
At sample collections, each animal was weighed and hair samples were collected during the
first 30 min after anaesthesia by shaving an area on the back of animals using an electric shaver.
Exactly the same dorsal surface was sampled each time to avoid any diluting effect of hair regrowth
before the stanazolol treatment period. Urine was collected by gently pressing the abdomen. The first
urine sample (urine 1) was collected 30 min after anaesthesia. The second urine (urine 2) sample was
collected after one hour of stanozolol and diclofenac injections. Blood samples were taken (along with
the urine 2 samples) from the tail vein one hour after stanozolol and diclofenac injection.
4.5. Sample Preparation
Serum and urine samples were stored at −80 ◦C. The LC-MS/MS methods developed for
stanozolol and its metabolite have been described previously [28]. Briefly, serum and urine samples
were thawed and vortexed with 100 µL used for analyses. Hair samples (50 mg) were decontaminated
with dichloromethane followed by sectioning into ca. 1 mm segments prior to incubation with 1 mL of
1 M sodium hydroxide (with the internal standard (I.S.) stanozolol D3) at 95 ◦C for 10 min. Hydrochloric
acid (1 M) was added to neutralise the homogenate, followed by addition of 2 mL of 0.2 M phosphate
buffer (pH 7.0), before a liquid-liquid extraction (LLE) step using 3.5 mL pentane [28]. Enzyme
digestion was utilised to determine the total concentration (glucuronide conjugated + unconjugated)
of stanozolol and 3′-hydroxystanozolol in each matrix (hair, urine and serum) [28]. The methods were
fully validated and lower limits of quantification (LLOQ) for stanozolol and 3′-hydroxystanozolol
were calculated to be 0.125 ng/mL and 0.25 ng/mL in urine respectively, in hair 0.5 pg/mg for both
analytes (using ca. 50 mg hair samples) and 0.25 ng/mL for both analytes in serum. The lower limits
of detection (LLOD) for stanozolol and 3′-hydroxystanozolol were 0.063 ng/mL and 0.125 ng/mL
in urine and serum, respectively. The LLOD in hair for stanozolol and 3′-hydroxystanozolol were
0.125 pg/mg and 0.25 pg/mg respectively, when ca. 50 mg hair was processed.
4.6. Statistical Analysis
For data analyses, levels below the LLOQ were treated as zero. The key research hypothesis,
namely the effect of diclofenac on detectability of stanozolol and/or its metabolite in different matrices,
was investigated with the sensitivity of the analytical tests for each matrix using the proportion of
false negatives. Group differences in stanozolol and 3′-hydroxystanozolol levels were tested at each
sampling point using mixed model ANOVA with single main effect test. To establish the magnitude of
the difference between groups, the effect size was also calculated and expressed as partial eta-squared.
Based on the study design that uses only one independent variable (treatment groups), eta-squared
values can be used to interpret effect sizes expressed as partial eta-square, thus values >0.02 were
considered a small effect, >0.13 were considered a medium effect, and >0.26 were considered a large
effect [29].
For a detailed analysis of the magnitude of the changes as the study progressed, average treatment
group levels of stanozolol and 3′-hydroxystanozolol from each sampling point were compared to
similar levels from the previous week using paired sample t-tests. Effect sizes for the paired samples
are expressed as Cohen’s d (small effect >0.2; medium effect >0.5; large effect >0.8), corrected for
dependency using Morris and DeShon’s equation 8 [30]. Owing to the large variations in stanozolol
and 3’-hydroxystanozolol within each group, coupled with the small sample size, changes over time in
the measured levels are interpreted based on effect size and not statistical significance. This approach
is in line with the growing trend of using effect size measures instead of statistical significance to allow
practically meaningful interpretations [31,32].
The relationship between hair levels of stanozolol and 3′-hydroxystanozolol and in urine and
blood was tentatively investigated by calculating correlation coefficients (Pearson’s r) as follows: levels
in hair at each measurement point (S3–S6) was correlated with levels measured two weeks prior to
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taking the hair sample in question, separately for each experimental group. Two week intervals were
selected based on the results showing that both stanozolol and 3′-hydroxystanozolol appeared in hair
in S2, 2 weeks after the treatment commenced. Owing to the small sample size, correlation coefficients
were limited to describe the strength and direction of the observed. The level of significance was set at
p < 0.05 for all analyses. All statistical analyses were performed using SPSS 21.0 (SPSS Inc., Chicago,
IL, USA).
5. Conclusions
An undisputable key result from this study is that following in vivo administration, stanozolol
and its metabolite 3′-hydroxystanozolol are quantifiable in hair samples at levels well above the
limit of quantification, and this is starkly in contrast to urinalysis, which appeared to be ineffective.
This marked contrast to urinalysis suggests that hair based analyses is a strong contender for future
doping tests, specifically for out of competition doping control, for synthetic steroids. A second
novel outcome is that the NSAID diclofenac has significant effects on the distribution of stanozolol
in vivo, with a reduction in urine levels to below the Minimum Required Performance Levels set by
WADA. Further research is warranted to fully develop this clear potential as a new anti-doping test for
synthetic steroids.
Supplementary Materials: Supplementary materials are available online. Table S1: Effect sizes for group
differences at each sampling point, Table S2: Test Sensitivity.
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